Leon-Castillo Alicia, Chrisinger John S A, Panse Gauri, Samdani Rashmi T, Ingram Davis R, Ravi Vinod, Prieto Victor G, Wang Wei-Lien, Lazar Alexander J
Pathology Service, Hospital Universitario Marques de Valdecilla, Santander, Spain.
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
J Cutan Pathol. 2017 Aug;44(8):692-697. doi: 10.1111/cup.12968. Epub 2017 Jun 19.
Cutaneous angiosarcoma can be challenging to diagnose particularly when poorly vasoformative and studied on biopsies. We report a case of a cutaneous angiosarcoma with strong positivity for tyrosinase, the first to our knowledge, initially misdiagnosed as melanoma. We subsequently evaluated the reactivity of panmelanocytic cocktail (tyrosinase, HMB-45 and Melan-A), SOX10, tyrosinase and MITF in a large tissue microarray (TMA) of angiosarcoma. The TMA included 142 cases of angiosarcomas (29 cutaneous, 22 primary breast, 41 post-radiation breast, 15 visceral, 26 deep soft tissue and bone, 5 chronic lymphedema-associated and 4 angiosarcomas arising in other sarcomas). Immunohistochemical studies were performed with anti-panmelanocytic cocktail, anti-SOX10, anti-MITF and anti-tyrosinase antibodies. TMA staining results were scored on intensity and percentage of tumoral labeling. Aside from the index case, no cases (0 of 133) showed positivity for tyrosinase including 28 cutaneous angiosarcomas. One breast angiosarcoma (1 of 131) was positive for MITF. All cases were negative for SOX10 and panmelanocytic cocktail (0 of 132). Angiosarcomas can rarely be positive for tyrosinase and MITF. Pathologists should be cognizant of these rare exceptions to prevent confusion with melanoma. Additional immunohistochemical markers for vascular and melanocytic differentiation, thorough histological examination for vasoformative and in situ areas as well as clinical impression are helpful in these exceptionally problematic cases.
皮肤血管肉瘤的诊断可能具有挑战性,尤其是在血管形成不良且通过活检进行研究时。我们报告了一例皮肤血管肉瘤,酪氨酸酶呈强阳性,据我们所知这是首例,最初被误诊为黑色素瘤。随后,我们在一个大型血管肉瘤组织微阵列(TMA)中评估了全黑素细胞组合(酪氨酸酶、HMB-45和Melan-A)、SOX10、酪氨酸酶和MITF的反应性。该TMA包括142例血管肉瘤(29例皮肤型、22例原发性乳腺型、41例放疗后乳腺型、15例内脏型、26例深部软组织和骨型、5例慢性淋巴水肿相关型以及4例由其他肉瘤引起的血管肉瘤)。使用抗全黑素细胞组合、抗SOX10、抗MITF和抗酪氨酸酶抗体进行免疫组织化学研究。根据肿瘤标记的强度和百分比对TMA染色结果进行评分。除索引病例外,没有病例(133例中的0例)显示酪氨酸酶阳性,包括28例皮肤血管肉瘤。1例乳腺血管肉瘤(131例中的1例)MITF呈阳性。所有病例SOX10和全黑素细胞组合均为阴性(132例中的0例)。血管肉瘤很少会出现酪氨酸酶和MITF阳性。病理学家应认识到这些罕见的例外情况,以防止与黑色素瘤混淆。在这些极其疑难的病例中,用于血管和黑素细胞分化的额外免疫组织化学标记、对血管形成区域和原位区域进行全面的组织学检查以及临床印象都很有帮助。